182 related articles for article (PubMed ID: 35734823)
21.
Park B; Liu GY
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271763
[TBL] [Abstract][Full Text] [Related]
22. [Hyper IgE syndrome: atopic dermatitis as first manifestation. Case report].
Carrera Dangond MM; Schellnast Faure A; Fernanda Vargas M; Regairaz L; Cabanillas D
Arch Argent Pediatr; 2021 Aug; 119(4):e370-e374. PubMed ID: 34309321
[TBL] [Abstract][Full Text] [Related]
23. A novel STAT3 mutation associated with hyper immunoglobulin E syndrome with a paucity of connective tissue signs.
Yoshida Y; Nagamori T; Takahashi H; Ishibazawa E; Shimada S; Kawai T; Azuma H
Pediatr Int; 2021 May; 63(5):510-515. PubMed ID: 32920916
[TBL] [Abstract][Full Text] [Related]
24. [Hyper-IgE syndromes].
He YY; Liu B; Xiao XP
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(11):892-896. PubMed ID: 29775011
[TBL] [Abstract][Full Text] [Related]
25. A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis.
Kasap N; Celik V; Isik S; Cennetoglu P; Kiykim A; Eltan SB; Nain E; Ogulur I; Baser D; Akkelle E; Celiksoy MH; Kocamis B; Cipe FE; Yucelten AD; Karakoc-Aydiner E; Ozen A; Baris S
Clin Immunol; 2021 Feb; 223():108645. PubMed ID: 33301882
[TBL] [Abstract][Full Text] [Related]
26. Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.
Matucci-Cerinic C; Viglizzo G; Pastorino C; Corcione A; Prigione I; Bocca P; Bustaffa M; Cecconi M; Gattorno M; Volpi S
Pediatr Allergy Immunol; 2022 Apr; 33(4):e13770. PubMed ID: 35470938
[No Abstract] [Full Text] [Related]
27. Th2 and Th9 responses in patients with chronic mucocutaneous candidiasis and hyper-IgE syndrome.
Becker KL; Rösler B; Wang X; Lachmandas E; Kamsteeg M; Jacobs CW; Joosten LA; Netea MG; van de Veerdonk FL
Clin Exp Allergy; 2016 Dec; 46(12):1564-1574. PubMed ID: 27474157
[TBL] [Abstract][Full Text] [Related]
28. Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations.
Chularojanamontri L; Wimoolchart S; Tuchinda P; Kulthanan K; Kiewjoy N
Asian Pac J Allergy Immunol; 2009 Dec; 27(4):233-6. PubMed ID: 20232578
[TBL] [Abstract][Full Text] [Related]
29. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis.
Schimke LF; Sawalle-Belohradsky J; Roesler J; Wollenberg A; Rack A; Borte M; Rieber N; Cremer R; Maass E; Dopfer R; Reichenbach J; Wahn V; Hoenig M; Jansson AF; Roesen-Wolff A; Schaub B; Seger R; Hill HR; Ochs HD; Torgerson TR; Belohradsky BH; Renner ED
J Allergy Clin Immunol; 2010 Sep; 126(3):611-7.e1. PubMed ID: 20816194
[TBL] [Abstract][Full Text] [Related]
31. Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome.
Alonso-Bello CD; Jiménez-Martínez MDC; Vargas-Camaño ME; Hierro-Orozco S; Ynga-Durand MA; Berrón-Ruiz L; Alcántara-Montiel JC; Santos-Argumedo L; Herrera-Sánchez DA; Lozano-Patiño F; Castrejón-Vázquez MI
Case Reports Immunol; 2019; 2019():6357256. PubMed ID: 31355024
[TBL] [Abstract][Full Text] [Related]
32. Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy.
Gracia-Darder I; Pons De Ves J; Reyero Cortina M; Martín-Santiago A
Dermatol Ther; 2022 Feb; 35(2):e15237. PubMed ID: 34850510
[No Abstract] [Full Text] [Related]
33. Acute disseminated encephalomyelitis: an uncommon presentation of hyper IgE syndrome.
Purkait R; Kar S; Bhadra R; Sinhamahapatra T
J Coll Physicians Surg Pak; 2014 Nov; 24 Suppl 3():S256-8. PubMed ID: 25518794
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous manifestations of Hyper IgE syndrome.
Minegishi Y; Saito M
Allergol Int; 2012 Jun; 61(2):191-6. PubMed ID: 22441639
[TBL] [Abstract][Full Text] [Related]
35. A challenging differential diagnosis in a patient with autosomal dominant STAT3 deficiency.
Bravo-Queipo-de-Llano B; Bonet D; Del Rosal T; Cámara C; Ruiz de Valbuena M; Pérez A; Grasa CD; Méndez-Echevarría A
Pediatr Pulmonol; 2023 Feb; 58(2):585-591. PubMed ID: 36267002
[TBL] [Abstract][Full Text] [Related]
36. Retained primary teeth in STAT3 hyper-IgE syndrome: early intervention in childhood is essential.
Meixner I; Hagl B; Kröner CI; Spielberger BD; Paschos E; Dückers G; Niehues T; Hesse R; Renner ED
Orphanet J Rare Dis; 2020 Sep; 15(1):244. PubMed ID: 32912316
[TBL] [Abstract][Full Text] [Related]
37. Undetectable interferon-alpha serum levels in a patient with atopic dermatitis.
Dolen JG; Mathur A
J Interferon Cytokine Res; 1995 Nov; 15(11):973-5. PubMed ID: 8590309
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome.
Lévy R; Béziat V; Barbieux C; Puel A; Bourrat E; Casanova JL; Hovnanian A
J Clin Immunol; 2020 Feb; 40(2):418-420. PubMed ID: 31993867
[No Abstract] [Full Text] [Related]
39. Pathogenesis of hyper IgE syndrome.
Heimall J; Freeman A; Holland SM
Clin Rev Allergy Immunol; 2010 Feb; 38(1):32-8. PubMed ID: 19452285
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Role of
Moffitt K; Cheung E; Manis J; Malley R
Infect Immun; 2018 May; 86(5):. PubMed ID: 29463618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
